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BaCkgRouND: First-generation cephalosporins and antistaphylo-
coccal penicillins are typically the first choice for treating skin and soft 
tissue infections (SSTI), but are not effective for infections caused by 
methicillin-resistant Staphylococcus aureus (MRSA). It is currently 
unclear what percentage of SSTIs is caused by community-associated 
MRSA in different regions in Canada. 
oBJECtIvEs: To determine the incidence of MRSA in children 
presenting to a pediatric emergency department with SSTI, and to 
determine which antibiotics were used to treat these infections.
MEthoDs: All visits to a pediatric emergency department were 
reviewed from April 15, 2010 to April 14, 2011. Diagnoses of cellulitis, 
abscess, impetigo, folliculitis and skin infection (not otherwise speci-
fied) were reviewed in detail to determine whether a culture was taken 
and which antibiotic was prescribed.
REsuLts: There were 367 cases of SSTI diagnosed over the study 
period. Forty-five (12.3%) patients had lesions that were swabbed for 
culture and sensitivity. S aureus was the most common organism found, 
with 14 (66%) methicillin-sensitive cases and seven (33%) methicillin-
resistant cases. Of the seven cases of MRSA identified, only one patient 
had clear risk factors for hospital-acquired MRSA. First-generation 
cephalosporins were initially prescribed for 280 (76%) patients. 
CoNCLusIoNs: The overall incidence of MRSA in the population 
presenting to a pediatric emergency department in Newfoundland and 
Labrador appeared to be low, although only a small percentage of 
infections were cultured. At this time, there appears to be no need to 
change empirical antibiotic coverage, which remains a first-generation 
cephalosporin.
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aureus; Pediatrics; Skin and soft tissue infections
Le Staphylococcus aureus résistant à la 
méthicilline d’origine non nosocomiale dans 
une salle d’urgence pédiatrique de terre-Neuve
hIstoRIQuE : Les céphalosporines de première génération et les 
pénicillines antistaphylococciques sont généralement le traitement de 
première intention des infections des tissus cutanés et des tissus mous 
(ITCM), mais ne sont pas efficaces contre les infections causées par le 
Staphylococcus aureus résistant à la méthicilline (SARM). On ne sait 
pas quel pourcentage d’ITCM est causé par un SARM d’origine non 
nosocomiale dans diverses régions du pays.
oBJECtIFs : Déterminer l’incidence de SARM chez les enfants qui 
consultent à une salle d’urgence pédiatrique en raison d’une ITCM, 
ainsi que les antibiotiques utilisés pour traiter ces infections.
MÉthoDoLogIE : Les chercheurs ont analysé toutes les visites à la 
salle d’urgence effectuées entre le 15 avril 2010 et le 14 avril 2011. Ils 
ont examiné attentivement les diagnostics de cellulite, d’abcès, 
d’impétigo, de folliculite et d’infection cutanée (non autrement spéci-
fiée) pour déterminer si une culture avait été effectuée et quel antibio-
tique avait été prescrit.
RÉsuLtats : Au total, 367 cas d’ITCM ont été diagnostiqués pendant 
la période de l’étude. Quarante-cinq patients (12,3 %) avaient des lésions 
qui avaient fait l’objet d’une analyse de culture et de sensibilité. Le 
S aureus était l’organisme le plus observé, 14 cas (66 %) étant sensibles à 
la méthicilline et sept (33 %) étant résistants à la méthicilline. Dans les 
sept cas de SARM, un seul patient présentait des facteurs de risque évi-
dents de SARM d’origine nosocomiale. Des céphalosporines de première 
génération avaient d’abord été prescrites à 280 patients (76 %).
CoNCLusIoNs : L’incidence globale de SARM au sein de la popula-
tion qui consulte à une salle d’urgence pédiatrique de Terre-Neuve-et-
Labrador semble faible, même si seulement un petit pourcentage de ces 
infections a fait l’objet d’une culture. À l’heure actuelle, il ne semble 
pas nécessaire de modifier la couverture antibiotique empirique, soit 
une céphalosporine de première génération.
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Methicillin-resistant Staphylococcus aureus (MRSA) first emerged in the 1960s, soon after the introduction of the antistaphylococ-
cal antibiotics (1). Initially, it was observed only as a hospital-acquired 
MRSA (HA-MRSA) infection (2,3). Beginning in the late 1980s, 
there were increasing reports of MRSA occurring in previously healthy 
patients who had no contact with the health care system (4,5). 
Community-associated MRSA (CA-MRSA) has different phenotypic 
and genetic characteristics than HA-MRSA. Risk factors for hospital-
acquired infection include prolonged hospitalization, dialysis, indwell-
ing catheters, admission to an intensive care unit, previous antibiotic 
therapy and surgical procedures. HA-MRSA is usually associated with 
pneumonia, urinary tract, bloodstream or surgical-site infections (6). 
CA-MRSA tends to cause infection in healthy, young individuals, and 
overwhelmingly causes skin and soft tissue infections (SSTIs) (1,6). 
Without proper treatment, these infections may progress to severe 
infections involving skin, muscle or bone (7-9). CA-MRSA can also 
cause severe illnesses such as necrotizing fasciitis, severe sepsis, and 
pneumonia with respiratory failure and death, especially in pediatric 
patients (5,9,10,11).
The typical agents causing SSTIs are Gram-positive organisms 
such as methicillin-sensitive S aureus and Streptococcus pyogenes. In 
the past, cultures were not routinely obtained because of the predict-
able etiology (5). Clinicians usually rely on the local prescribing guide-
lines for choosing appropriate antibiotic therapy. These guidelines 
need to reflect the risk of an infection being caused by MRSA (12). 
First-generation cephalosporins and antistaphylococcal penicillins are 
origiNaL artiCLe
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typically the first choice for SSTIs, meaning that many MRSA infec-
tions may not be initially properly treated (2). Because some strains of 
CA-MRSA are extremely virulent, it is not recommended to withhold 
appropriate antibiotic treatment in unwell individuals when 
CA-MRSA may be the causative organism (12). Some hospitals have 
changed their recommendations for first-line empirical treatment of 
SSTIs based on the high prevalence of MRSA in their community 
(13,14). In any case, it is now important that cultures of SSTIs are 
obtained to monitor CA-MRSA in the community as well as guide 
appropriate antibiotic therapy (14). Because of the differences in the 
treatment of the infections, it is important for clinicians to be aware of 
the incidence of HA-MRSA and CA-MRSA in their communities to 
make appropriate first-line treatment choices. 
CA-MRSA is not a reportable disease in Canada; while some prov-
inces track infection rates (1), the rate of incidence is unknown for 
many parts of the country. There is evidence that CA-MRSA rates 
vary across regions and that it may have higher incidence rates than 
HA-MRSA in some areas. In patients presenting to an emergency 
department in California (USA) with an SSTI, MRSA was present in 
almost 50% of infections. Seventy-five per cent of those infections 
were classified as CA-MRSA (14). A study at a large hospital in 
Georgia (USA) showed that 72% of SSTIs were caused by MRSA, 
and 63% of those were community associated (15). There is also evi-
dence that rates of CA-MRSA are increasing in some regions. For 
example, a surveillance study in Minnesota (USA) found that the 
number of MRSA cases classified as community associated increased 
from 11% to 33% in six years (16).
In the present study, we examined the rates of HA-MRSA and 
CA-MRSA identified in SSTIs in Newfoundland and Labrador, a prov-
ince for which little is known about the rates of MRSA, particularly in 
the pediatric population. The Newfoundland Department of Health and 
Community Services releases quarterly reports on the incidence of 
MRSA in the various health regions; however, these reports do not 
specify patient age nor type of infection. The emergency department is 
a key place in a health care facility for first identifying infections and is 
likely to encounter the most cases of CA-MRSA. Because of the pos-
sible severity of infections in children, we focused on identifying rates at 
the only pediatric emergency department in Newfoundland and 
Labrador. The Janeway Children’s Health and Rehabilitation Centre 
(St John’s, Newfoundland and Labrador) is the only tertiary care chil-
dren’s hospital in Newfoundland and Labrador. It has approximately 
30,000 patient visits to its emergency department each year (17). As the 
province’s only pediatric tertiary care centre, its emergency department 
sees patients from all parts of the province, although the majority are 
from the St John’s area. We examined the incidence of both CA-MRSA 
and HA-MRSA in patients presenting to the Janeway Emergency 
Department with SSTIs. Specifically, we sought to determine the organ-
isms responsible for infection and the antibiotic used for treatment.
MEthoDs
The records for all visits to the Janeway Emergency Department were 
reviewed using data recorded by emergency department staff for the 
period between April 15, 2010 and April 14, 2011. The discharge 
diagnosis as recorded on the emergency room chart was used to iden-
tify all patients diagnosed with cellulitis, abscess, folliculitis, impetigo 
and skin infection (not otherwise specified). The medical records were 
reviewed in detail to determine whether a culture had been obtained, 
the results of the culture and the antibiotic that had been prescribed. 
The diagnosis of periorbital cellulitis was excluded; it would be very 
rare for a periorbital cellulitis to have a lesion amenable to culturing. 
Staphylococcus was identified in the microbiology laboratory based on 
Gram reaction and shape, and confirmed using catalase and latex agglu-
tination for clumping factor, protein A and capsular polysaccharides (all 
assessed using Pastorex Staph-Plus [Biorad, USA]). Identification and 
susceptibility was performed using a MicroScan GP34 panel (Siemens, 
Germany),  and discrepancies or questionable susceptibility were con-
firmed using Kirby Bauer testing. If a patient was found to have MRSA, 
risk factors for CA-MRSA were assessed using the clinical criteria for 
the definition of CA-MRSA according to the Centers for Disease 
Control and Prevention (Georgia, USA) (18). The research protocol 
was approved by the Human Investigation Committee at Memorial 
University (St John’s, Newfoundland and Labrador).
REsuLts
Records were reviewed for all patient visits occurring between April 
15, 2010 and April 14, 2011, except for the month of February 2011. 
These records could not be located and, therefore, were not reviewed. 
A total of 367 patients were identified as having a SSTI during the 
11 months for which data were reviewed. There were 167 cases of cel-
lulitis, 82 cases labelled as skin infection (not otherwise specified) and 
45 cases of abscess. Impetigo was identified in 33 patients, and 
40 patients had diagnoses such as folliculitis and infected ingrown 
toenail (classified as ‘other’) (Figure 1). Forty-five patients (12.3%) 
had lesions that were swabbed, and sent for culture and sensitivity 
analysis. Nine cases of cellulitis (5.4%), nine skin infections (11%), 
26 abscesses (57.8%) and one case of impetigo (3.0%) were cultured. 
No infection identified as ‘other’ was cultured. 
Of the 45 cases for which cultures were taken, the causative organ-
ism was S aureus in 21 (46%). Coagulase-negative Staphylococcus was 
identified in nine patients (20%) and no growth was identified in 
seven patients (16%) despite having their lesion swabbed (Figure 2). 
Other organisms that were identified less frequently included coli-
forms in five cases, group A streptococcus in one case and anaerobic 
bacteria in two cases. Multiple organisms were identified in seven 
Figure 1) Number of cases of skin and soft tissue infection identified and 
the number of cultures taken between April 2010 and April 2011 according 
to type of infection Figure 2) Etiological organism for cultured skin and soft tissue infections. 
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cases. Fourteen cases (66%) in which S aureus was isolated were 
methicillin sensitive, and seven (33%) were methicillin resistant. 
Of the seven cases of MRSA identified, one case was in a patient 
who had undergone open heart surgery at a hospital outside the prov-
ince. Another patient was from Labrador. The other five patients lived 
in and around the St John’s area and had no identifiable risk factors for 
a hospital-acquired infection on review of their medical records. The 
antibiotic susceptibility patterns for all seven patients were the same. 
The isolates were universally sensitive to clindamycin, trimethoprim-
sulfamethoxazole (TMP-SMZ) and vancomycin, and universally 
resistant to erythromycin, amoxicillin-clavulanic acid and the first-
generation cephalosporins. First-generation cephalosporins were over-
whelmingly the antibiotic of choice for the treatment of SSTIs, being 
selected nearly 75% of the time (Figure 3). Other commonly pre-
scribed antibiotics included third-generation cephalosporins (ceftriax-
one in 3.8% of cases and cefotaxime in 1.3%), clindamycin (4%), and 
cloxacillin (2%) and amoxicillin-clavulanic acid (2%). Topical anti-
biotics were used in 4.9% of cases.
DIsCussIoN
To the best of our knowledge, the present study is the first to report 
on pediatric MRSA in Newfoundland and Labrador. There were 
367 cases of skin infection identified during the 11 months between 
April 15, 2010 and April 14, 2011. Of these, 12.3% had samples 
obtained for culture and sensitivity. While some infections were 
unlikely to be amenable to culture, all abscesses should undergo inci-
sion and drainage, and lesions with discharge, especially those that 
do not respond to initial treatment, should be cultured (19). The 
culture rate of 12.3% appears to be lower compared with other stud-
ies that have investigated SSTIs, in which rates have ranged from 
17% to as high as 50% to 100% (20-22). It is unclear why the culture 
rate in the present study was lower.
The incidence of MRSA during the 11 months studied was <2% of 
all skin infections. However, in infections for which cultures had been 
taken, MRSA accounted for 15.6% of the organisms and 33% of 
S aureus isolates. In only one instance was there a clear link to a 
hospital-acquired infection. Uncomplicated skin abscesses in children 
>3 months of age can be managed by incision and drainage alone, 
coupled with close follow-up (19). Guidelines published in 2006 sug-
gested that when more than 10% to 15% of the S aureus isolates are 
MRSA, empirical therapy for infections should include coverage for 
MRSA (23). Because microbiological diagnosis was obtained in only a 
few cases, it is difficult to determine the true rate of MRSA infection in 
children in the province; however, based on the data available, it 
appears that we may be reaching this threshold. Further surveillance is, 
therefore, warranted. 
All MRSA isolates exhibited the same sensitivity profile and were 
sensitive to clindamycin, TMP-SMZ and vancomycin. In general, 
CA-MRSA tends to display the same broad sensitivity patterns, while 
HA-MRSA tends to be resistant to nearly all antibiotics except vanco-
mycin and other antibiotics not tested here (eg, linezolid). Review of 
medical records also revealed only one patient with clear risk factors 
for HA-MRSA, having undergone open heart surgery in another prov-
ince. The rest of the cases appeared to occur in otherwise healthy 
individuals, indicating that MRSA is in the community.
The present study had a number of limitations. One of the key 
barriers to the study was that the required information regarding 
emergency visits was only available in paper records. This format of 
storing patient records made the review very time consuming and 
likely limits the ability to easily identify changes in the infection 
patterns of SSTI in the pediatric population. It also increases the risk 
of loss of patient information. The paper record for the month of 
February 2011 was misplaced and could not be located to be reviewed 
for the present study. In the months immediately preceding and fol-
lowing February, approximately 20 skin infections were identified 
and an average of five swabs taken. It is not possible to speculate on 
whether any of the skin infections in February may have been caused 
by MRSA. Another weakness was relying on the discharge diagnoses 
from the emergency room documentation to identify cases. In some 
instances, there was no diagnosis listed, or it was unclear what the 
diagnosis was. In these cases, every attempt was made to identify the 
hospital chart number and verify the visit, but there may have been 
some cases that were missed. Having accurate electronic records 
would have helped to avoid some of these issues. The study did not 
attempt to determine the levels of infection identified in other cen-
tres across the province and it is not known how many cases would 
have been missed. The finding that infections are swabbed at such a 
low rate also hampered the determination of more accurate rates of 
MRSA in the pediatric population in the province.
The present study found that while the overall prevalence of MRSA 
in patients sampled was low, when microbiological diagnosis was obtained, 
cases of what appear to be CA-MRSA exist. The incidence of CA-MRSA 
is currently too low to recommend changing the first-line antibiotic treat-
ment, which is a first-generation cephalosporin. Follow-up needs to be 
assured, and for infections that do not appear to be responding to first-line 
treatment, MRSA should be considered in the differential diagnosis. 
Antibiotic coverage should be changed to account for this; options may 
include TMP-SMZ or clindamycin. The study also highlighted the low 
number of cultures taken from skin lesions and the need to review 
whether taking a greater percentage of cultures from SSTIs would be 
appropriate. Finally, while the percentage of MRSA infections identified 
in the SSTIs is low, the higher percentage of MRSA infections in the 
SSTIs for which cultures were taken supports the conclusion that further 
surveillance of the incidence of the CA-MRSA in the pediatric popula-
tion in Newfoundland and Labrador is warranted.
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